Health News Releases

  • Today May 21
November 10, 2015 18:25
Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care
Brigham and Women’s Hospital in Boston, U.S., and Boehringer Ingelheim announce the results of a new interim analysis from a long-term study evaluating the safety and effectiveness of Pradaxa® (dabiga
November 10, 2015 17:15
Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran
Boehringer Ingelheim announces results from two new analyses evaluating idarucizumab, recently approved under the Accelerated Approval pathway and marketed in the U. S. as Praxbind®, a specific revers
November 10, 2015 14:00
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
New sub-analysis data presented today show the reduction in risk for hospitalisation for heart failure or cardiovascular (CV) death with Jardiance®, compared with placebo when added to standard of car
November 10, 2015 10:55
Quintiles Contributes Open Source Code to ResearchKit
Quintiles, the world’s largest biopharma services provider, has announced its contribution of enhancements to the ResearchKit framework which was designed by Apple to make it easy for researchers to g
November 09, 2015 22:00
Replicor Announces Grant of US Patents on HBV / HDV Treatment Methods Combining HBsAg Reduction and Immunotherapy
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces all
November 09, 2015 13:25
EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015
Boehringer Ingelheim and Eli Lilly and Company today announced that top-line renal results from the EMPA-REG OUTCOME® study (compound empagliflozin, marketed under the name Jardiance®) will be present
November 09, 2015 11:10
Takeda to Present Data from Ixazomib’s Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502, http://goo.gl/eX9kbP) today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society o
November 06, 2015 13:55
Founder Dennis Gillings to Retire as Quintiles Executive Chairman at Close of 2015
Quintiles Founder Dr. Dennis Gillings, CBE, will retire from his position as Executive Chairman of Quintiles Transnational Holdings Inc. (NYSE: Q) at the end of this year, December 31, 2015. Dr. Gilli
November 06, 2015 13:30
Research Finds Cranberries are an Effective Approach to Help Reduce Antibiotic Use
An international team of scientists presented new evidence showing how cranberries are poised to be a compelling tool to help reduce antibiotic resistance and oxidative stress. This Smart News Rele
November 05, 2015 14:00
Cell Signaling Technology Announces the Release of 6 New Monoclonal Antibodies for Tumor Immunology Research.
Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, announced today the release of 6 new monoclonal antibodies (mAb) for tumor immunology research. This announcement was made at
November 05, 2015 13:10
Pharco Pharmaceuticals, Inc. Announces Late-Breaker Oral Presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2015
Pharco Pharmaceuticals, Inc. announced today that Gamal Esmat, M.D., Professor of Haepatology and Endemic Medicine at Cairo University and WHO viral hepatitis expert, will present advanced results of
November 05, 2015 12:10
Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer
Not intended for UK-based media Merck and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanc
November 05, 2015 10:45
Singapore General Hospital and Thermo Fisher Scientific Collaborate to Identify the Prevalence of Asian-Specific Genetic Mutations in Cancer
Singapore General Hospital (SGH) and Thermo Fisher Scientific today announced the establishment of a collaborative partnership that will work to identify cancer genetic mutations linked with Asian pop
November 03, 2015 17:25
Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound
Boehringer Ingelheim today announced at the BIO-Europe® conference in Munich, Germany, the initiation of a global Phase II trial evaluating the efficacy and safety of BI 1482694 (HM61713) in patients
Institut Pasteur Korea held a press conference on November 2, 2015. Researchers addressed the curren
November 03, 2015 07:00
IPK Discusses MERS/Ebola Research Status and Korea’s Response Strategies Against Infectious Diseases
During a press conference held at Korea Press Center on November 2, 2015; Institut Pasteur Korea (IPK, CEO: Dr. Hakim Djaballah) addressed the current research status on MERS and Ebola virus infection
November 02, 2015 15:20
Multi-Stakeholder Study Reveals That Clinical Research Participation Leads to Higher Patient Engagement, Reduced Cost of Care
Quintiles (www.quintiles.com), the world’s largest provider of product development and integrated healthcare services, today published new research that reveals high levels of patient satisfaction and
November 02, 2015 14:50
Takeda Reports Results for the First Half of FY2015…Confirms Management Guidance for the Full Year
Takeda Pharmaceutical Company Limited (TOKYO:4502): First half results aligned with management guidance · Underlying revenue +3.8% year-to-year (reported revenue growing +6.2% to 904 billion yen
October 31, 2015 17:00
Mannatech Launches Brain-supporting Cognitate™ Supplement in Korea at Company’s Biggest Global Event
Mannatech, Incorporated (http://us.mannatech.com) (NASDAQ: MTEX, http://goo.gl/SP6Q2G), the founder of the M5M℠ (Mission 5 Million℠) Foundation (http://m5mfoundation.org), the pioneer of nutritional g
October 31, 2015 09:00
Mannatech Launches Freshden Toothpaste Containing Natural Ingredients at Global Event in Korea
Mannatech, Incorporated (http://us.mannatech.com) (NASDAQ: MTEX, http://goo.gl/SP6Q2G), the founder of the M5M℠ (Mission 5 Million℠) Foundation (http://m5mfoundation.org), the pioneer of nutritional g
October 30, 2015 16:55
Two New Clinical Studies Using Masimo Technologies Presented at the American Society of Anesthesiologists Annual Meeting
Masimo (www.masimo.com) (NASDAQ: MASI) announced today that two new studies using Masimo technologies were presented at the American Society of Anesthesiologists (ASA) annual meeting in San Diego, Cal
October 29, 2015 23:55
Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab
Boehringer Ingelheim today announced results from a Phase I study (NCT02045979, https://goo.gl/ZaRHyV) of its biosimilar candidate (BI695501) for adalimumab (AbbVie’s Humira®), that demonstrated pharm
October 29, 2015 23:50
CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®
Boehringer Ingelheim today announced the presentation of several new post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 studies at the American College of CHEST Physicians Annual Meeting in Montre
October 29, 2015 14:20
Terumo BCT Completes the First Clinical Study Reducing Malaria Transmission from Whole Blood Transfusions with Pathogen Reduction Technology
In low-income countries, 69 percent of collected blood is transfused as whole blood (WB) rather than blood components.[1] However, health care professionals have had no proven method to inactivate har
October 29, 2015 13:30
Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)
Seattle Genetics, Inc. (www.seattlegenetics.com) (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (www.takeda.com) (TSE:4502) today announced that the companies have achieved completion of tar
October 28, 2015 13:50
Masimo Announces FDA 510(k) Clearance for MightySat™ Rx Fingertip Pulse Oximeter
Masimo (NASDAQ: MASI) announced today FDA 510(k) clearance for MightySat Rx, a fingertip pulse oximeter that incorporates Masimo SET® Measure-through Motion and Low Perfusion™ technology. This Smar
25 per page50 per page75 per page100 per page